Magic™ TCR Repertoire Analysis for Minimal Residual Disease Quantification
TypeName: Business Offer
Category:
Offer Date:2019/04/05
Country: United States
Summary: Creative Biolabs has applied our advanced Magic™ TCR repertoire analysis platform to MRD quantification for highly accurate and reproducible results. Our method requires no per-patient customization, thus combining the benefits of high sensitivity and universal applicability. To achieve accurate MRD quantification, Creative Biolabs also developed a systematic bioinformatics methodology to aggregate cancer clone sequence variants arising from systematic and random artifacts occurring during NGS. https://www.creative-biolabs.com/tcr-repertoire-analysis-for-minimal-residual-disease-quantification.html
Agriculture & Food
Business Services
Electronics, IT and Telecoms
Leisure & Tourism
Minerals
Textiles, Clothing, Leather,
Transport & Logistics
